Keratoconus affects not only the cornea but also the retina, choroid, and optic nerve head, as shown in a meta-analysis co-authored by Prof. Farhad Hafezi.
A new publication in JRS reports the long-term endothelial safety of the ELZA-sub400 protocol for treating progressive keratoconus in corneas thinner than 400 µm.
Transepithelial corneal cross-linking offers a new epi-on CXL protocol with biomechanical outcomes comparable to accelerated epi-off CXL for keratoconus treatment
ELZA’s cornea, cataract, and refractive surgeon, Dr. Emilio Torres-Netto, MD, PhD, FWCRS, was this month appointed by the European Journal of Ophthalmology (EJO) as an Associate Editor. This honor is a reflection of Dr. Torres-Netto’s knowledge, experience, and commitment to the field of ophthalmology.
New CXL research challenges the role of oxygen in corneal cross-linking. Can oxygen-independent CXL improve keratoconus treatment? Find out how this breakthrough could change clinical practice.
Dual chromophore PACK-CXL treatment using riboflavin/UV-A and rose bengal/green light may offer an effective solution for refractory Acanthamoeba keratitis.
Our latest review on corneal cross-linking (CXL), published in Progress in Retinal and Eye Research, explores its evolution, advanced protocols like ELZA-PACE, and clinical applications.
